New pill combo aims to tackle tough lymphoma when other treatments fail
NCT ID NCT04442022
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at one of two doses plus R-GDP, or a placebo plus R-GDP, for up to 6 cycles. The goal is to see if the combination improves response rates and delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selinexor (a targeted cancer drug taken as a pill)
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat diffuse large B-cell lymphoma who cannot have a stem cell transplant or CAR-T therapy.
- What could go wrong
- This is an early-to-mid stage trial, so the added benefit of selinexor is not yet proven. Side effects from the combination chemotherapy may be significant, and the drug may not improve outcomes enough to change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AOU City of Health and Science of Turin
Turin, Torino, 10126, Italy
-
AOU Maggiore della Carità SCDU Ematologia
Novara, Novara, 28100, Italy
-
AOU Ospedali Riuniti-Università Politecnica delle Marche Clinica di Ematologia
Ancona, Ancona, 60020, Italy
-
Arizona Oncology Associates
Tucson, Arizona, 85711, United States
-
Assuta Ashdod Medical Center
Ashdod, 7747629, Israel
-
Assuta medical centers - Ramat Hachayal
Tel Aviv, 6423906, Israel
-
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Palermo, Sicily, 90146, Italy
-
CM Pratia Poznań
Skorzewo, Wielkopolska, 60819, Poland
-
DIP. Oncologia- Ematologia, UOSD Centro Diagnosie TerapiaDei Linfomi
Pescara, Pescara, 65124, Italy
-
Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 02-781, Poland
-
Fondatione Policlinico Universitario A. Gemelli
Rome, Rome, 00168, Italy
-
Hospital Universitario La Paz
Madrid, Madrid, 28046, Spain
-
Hospital Vall Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Virgen del Rocío
Seville, Seville, 41013, Spain
-
Huaxi Hospital Sichuan University
Chengdu, Sichuan, 610044, China
-
Institut Catala D'oncolocia
Barcelona, Barcelona, 09809, Spain
-
Institut català d'oncologia-hospital germans trias i pujol
Badalona, Barcelona, 08916, Spain
-
Institute of Hematology and Transfusion Medicine
Warsaw, 00-791, Poland
-
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Chandler, Arizona, 85224, United States
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wrocławiu
Wroclaw, Radeckiego, 50-367, Poland
-
National Cancer Institute
Naples, Napoli, 1-80131, Italy
-
Norton Cancer Institute, St. Matthews
Louisville, Kentucky, 40207, United States
-
Pratia MCM Krakow
Krakow, Lesser, 30-510, Poland
-
Pratia Onkologia Katowice
Katowice, Silesian Voivodeship, 40-523, Poland
-
Rabin Medical Center
Petah Tikva, 4941492, Israel
-
Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
Huangpu, Shanghai Municipality, 200025, China
-
Soroka Medical Center
Beersheba, 8457108, Israel
-
Stony Brook
Stony Brook, New York, 11794, United States
-
Szpitale pomorskie gdynia dept of haematology
Gdynia, Pomeranian Voivodeship, 81-519, Poland
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The Oncology Institute (TOI) Clinical Research
Cerritos, California, 90703, United States
-
The University of Texas Health Science Center at Tyler DBA UT Health East Texas HOPE Cancer Center
Tyler, Texas, 75702, United States
-
The first affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
UOC Ematologia ad Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano"
Caserta, Caserta, 81100, Italy
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
Zhongshan Hospital Fudan University
Xuhui, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- New drug cocktail aims to tackle tough lymphoma
- Radiation and immunotherapy team up against hard-to-treat lymphoma